Description

Description

Erli Plus XR (25mg/1000mg) is a fixed-dose combination medicine manufactured by PharmaEvo, formulated with Empagliflozin 25mg and extended-release Metformin 1000mg in each tablet. This pack contains 14 tablets and represents the higher-strength Empagliflozin variant within the Erli Plus XR range, intended for adults with type 2 diabetes mellitus who require a more pronounced SGLT2-inhibiting effect alongside sustained Metformin action. This strength is typically prescribed for patients who have already tolerated and responded to the 12.5mg Empagliflozin dose but require further improvement in blood sugar control, or for those whose physician determines that the higher dose is appropriate from the outset based on individual glycemic targets. Metformin works by reducing glucose production in the liver and improving the body’s sensitivity to insulin, while the extended-release formulation allows for a gradual, steady release of the medicine throughout the day, supporting once-daily dosing and potentially reducing gastrointestinal side effects compared to immediate-release versions. Empagliflozin adds a complementary mechanism by helping the kidneys excrete excess glucose through urine. Together, this combination is intended to offer stronger, more comprehensive glycemic support for patients requiring intensified therapy. Erli Plus XR should always be used as part of a broader diabetes management plan that includes appropriate diet, physical activity, and regular blood sugar monitoring, under the ongoing supervision of a qualified healthcare provider.

Ingredients

Each tablet of Erli Plus XR (25/1000mg) contains two active pharmaceutical ingredients: Empagliflozin 25mg, an SGLT2 inhibitor that promotes glucose excretion through the kidneys at a higher strength than the standard combination doses, and Metformin Hydrochloride 1000mg in extended-release form, a biguanide-class antidiabetic agent that reduces hepatic glucose output and enhances insulin sensitivity. The tablet also contains specialized extended-release excipients and film-coating agents that regulate the gradual release of Metformin, along with standard pharmaceutical binders that support overall tablet stability.

Dosage Form

Erli Plus XR (25/1000mg) is available as an oral extended-release film-coated tablet, delivering a combined strength of 25mg Empagliflozin and 1000mg extended-release Metformin per tablet. The pack contains 14 tablets, formulated for once-daily administration and representing the higher-dose option within the Erli Plus XR range, as directed by a treating physician.

Uses

Erli Plus XR (25/1000mg) is used to help improve blood sugar control in adults with type 2 diabetes mellitus who require a stronger dose of Empagliflozin in combination with extended-release Metformin. It is often prescribed for patients who need further glycemic improvement beyond what the 12.5mg strength provides, or for those with higher blood sugar targets that warrant more intensive combination therapy from the start. It may also be used alongside other antidiabetic medicines as part of a comprehensive treatment strategy. This medicine is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis.

How to Use

Erli Plus XR tablets are typically taken once daily with the evening meal, or as otherwise directed by a doctor, to support consistent absorption and minimize gastrointestinal discomfort. The tablet must be swallowed whole with a glass of water and should never be crushed, split, or chewed, as this would disrupt the extended-release mechanism and cause the medicine to be released too rapidly. It is not unusual to notice a tablet-shaped residue in the stool, which reflects the outer shell of the extended-release system passing through the digestive tract after the active ingredients have been absorbed. Dosage and treatment duration should strictly follow the prescribing physician’s instructions, and if a dose is missed, it should be taken as soon as remembered unless it is close to the time of the next scheduled dose, in which case the missed dose should be skipped rather than doubled.

Side Effects

Erli Plus XR (25/1000mg) may cause side effects in some individuals, and the higher Empagliflozin strength may slightly increase the likelihood of certain effects related to increased urinary glucose excretion. Commonly reported effects include urinary tract infections, genital yeast infections, and increased urination, along with gastrointestinal symptoms such as nausea, mild diarrhea, or stomach discomfort, particularly when treatment is first started. Some patients may also experience dizziness, mild dehydration, or a metallic taste in the mouth. In rare cases, more serious effects such as lactic acidosis (associated with Metformin) or ketoacidosis (associated with Empagliflozin) may occur, and immediate medical attention should be sought if symptoms such as severe abdominal pain, unusual fatigue, rapid breathing, or persistent vomiting develop.

Pregnancy & Breastfeeding

Erli Plus XR (25/1000mg) is generally not recommended during pregnancy. While Metformin has been used in select pregnancy-related situations under close medical supervision, the Empagliflozin component, particularly at this higher strength, carries potential risks to fetal development in later pregnancy stages, and this combination is typically avoided unless a specialist advises otherwise. Women who are pregnant, planning pregnancy, or suspect they may be pregnant should inform their doctor immediately. The safety of this combination during breastfeeding has not been well established, and alternative treatment options are usually considered for nursing mothers. Any use during pregnancy or breastfeeding should be decided only in consultation with a qualified healthcare provider.

Storage Instructions

Erli Plus XR tablets should be stored at room temperature, in a cool, dry place away from direct sunlight, heat, and excess moisture. Tablets should be kept in their original packaging until ready for use to protect the extended-release coating from environmental exposure. Store out of reach of children and pets, and do not use the medication beyond its printed expiry date. Unused or expired tablets should be disposed of responsibly according to local pharmaceutical disposal guidelines, rather than discarded with regular household waste.

FAQs

How is the 25mg strength different from the 12.5mg version?
The 25mg strength delivers a higher dose of Empagliflozin, intended for patients who need a stronger glucose-lowering effect than the lower-strength combination provides, as determined by their doctor.

Can I move directly from Erli Plus XR 12.5/1000mg to this 25/1000mg version?
Any change in Empagliflozin strength should only be made under a doctor’s supervision, as it may require monitoring of blood sugar response and kidney function.

Why is once-daily dosing possible with this tablet?
The extended-release Metformin component gradually releases the medicine over the day, allowing for once-daily dosing instead of the multiple daily doses typically needed with immediate-release Metformin.

Do I need extra monitoring on the higher Empagliflozin dose?
Yes, your doctor may recommend more frequent monitoring of kidney function, hydration status, and blood sugar levels while on the higher-strength combination.

Disclaimer

Always use this medicine strictly according to your doctor’s instructions and prescribed dosage.